10-Q: Rapport Therapeutics Reports Q3 2026 Results, Advances Pipeline
Quarterly Report
Rapport Therapeutics, Inc. filed its Form 10-Q for the quarter ended September 30, 2026, detailing progress in its neurological disorder drug development, including positive Phase 2 results for RAP-219 and a significant capital raise.
Summary
- Rapport Therapeutics, a clinical-stage biotechnology company focused on neurological and psychiatric disorders, filed its quarterly report for the period ending September 30, 2026.
- The company reported a net loss of $40.2 million for the three months ended September 30, 2026, compared to a net loss of $26.9 million for the same period in 2025.
- For the nine months ended September 30, 2026, the net loss was $116.7 million, compared to $77.7 million for the same period in 2025.
- As of September 30, 2026, the company had $395.0 million in cash, cash equivalents, and short-term investments.
- Significant progress was made in advancing the RAP-219 program, with Phase 3 trials initiated for focal onset seizures (FOS) and positive topline results announced for bipolar mania.
- The company completed a substantial capital raise in October 2026, generating approximately $410.7 million in net proceeds.
- The company expects its current cash, cash equivalents, and short-term investments, along with the proceeds from the October 2026 offerings, to fund operations through the end of 2029.
Sentiment
Score: 4
Explanation: StockSavvy.ai views this filing as cautiously optimistic, with significant progress in clinical trials and a substantial capital raise, but tempered by ongoing substantial losses and the inherent risks of drug development.
Positives
- Positive topline results from the Phase 2 trial of RAP-219 in acute mania associated with bipolar I disorder, meeting its primary endpoint with a statistically significant improvement over placebo.
- Initiation of two parallel Phase 3 pivotal trials (FOCUS 1 and FOCUS 2) for RAP-219 in patients with drug-resistant FOS.
- Successful completion of a significant capital raise in October 2026, generating approximately $410.7 million in net proceeds from equity and convertible note offerings.
- Extended cash runway, with management expecting sufficient funds to support operations through the end of 2029.
- FDA removed the clinical hold on the DPNP IND for RAP-219 in December 2025, although further investment in this program is deferred.
- The company received a $20.0 million non-refundable upfront payment from Tenacia Biotechnology for the license of RAP-219 in China.
Negatives
- Continued significant operating losses, with a net loss of $40.2 million for the three months ended September 30, 2026, and an accumulated deficit of $351.9 million as of that date.
- Increased research and development expenses, up 53.9% to $118.4 million for the nine months ended September 30, 2026, compared to the prior year period, driven by advancing clinical trials.
- Increased selling, general, and administrative expenses, up 39.0% to $30.7 million for the nine months ended September 30, 2026.
- The company will require substantial additional capital in the future to fund its ongoing operations and growth strategy.
- The company's business is highly dependent on the success of its product candidates, particularly RAP-219, and any failure in clinical development or regulatory approval would materially harm the business.
Risks
- The company is a clinical-stage biotechnology company with a limited operating history and has incurred significant financial losses since inception, with no assurance of future profitability.
- The successful development and commercialization of product candidates are highly uncertain and dependent on lengthy, expensive, and unpredictable regulatory approval processes.
- The company will require substantial additional funding to finance operations, and failure to raise capital when needed could force delays or elimination of product development programs.
- Product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit commercial profile, or result in significant negative consequences.
- The company relies on third parties for clinical trials and manufacturing, and their performance or failure to comply with regulations could substantially harm the business.
- The company depends on in-licensed intellectual property, and failure to comply with license obligations could result in loss of important license rights.
- The company's indebtedness, including the recently issued convertible senior notes, could limit cash flow available for operations and expose it to financial risks.
- The market for the company's securities may not be sustained, and the price could be volatile due to various factors, including clinical trial results and regulatory decisions.
Future Outlook
The company expects its cash, cash equivalents, and short-term investments, along with proceeds from recent offerings, to fund operations through at least 12 months from the issuance of the financial statements, and anticipates funding through the end of 2029. However, substantial additional capital will be required for ongoing operations and growth, with potential financing through equity offerings, debt financings, or collaborations.
Management Comments
- Stock-based compensation expense for stock options was $7.2 million and $4.2 million in the three months ended September 30, 2026 and 2025, respectively, and $20.7 million and $11.4 million in the nine months ended September 30, 2026 and 2025, respectively.
- Research and development expenses were $34.3 million for the three months ended September 30, 2026, compared to $22.3 million for the same period in 2025, an increase of $12.0 million.
- Selling, general and administrative expenses were $9.8 million for the three months ended September 30, 2026, compared to $7.7 million for the same period in 2025, an increase of $2.1 million.
- Interest income was $3.9 million for the three months ended September 30, 2026, compared to $3.1 million for the same period in 2025, an increase of $0.8 million.
Industry Context
StockSavvy.ai notes that Rapport Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, specifically focusing on neurological and psychiatric disorders. The company's strategy of developing precision medicines based on its RAP technology platform aims to address the limitations of conventional treatments, which often suffer from off-target effects. The recent positive clinical trial data and substantial capital raise position the company to advance its pipeline, but the inherent risks and long development timelines characteristic of the industry remain significant.
Comparison to Industry Standards
- Rapport Therapeutics' net loss of $40.2 million for the quarter and $116.7 million for the nine months ended September 30, 2026, is substantial but not unusual for a clinical-stage biotechnology company investing heavily in R&D.
- The company's cash burn rate, reflected in its net cash used in operating activities of $96.1 million for the nine months ended September 30, 2026, is consistent with industry peers in advanced clinical development stages.
- The $20.0 million upfront payment from Tenacia is a common structure for early-stage licensing deals in the pharmaceutical industry, providing non-dilutive capital and validating the technology.
- The company's reliance on stock-based compensation, with $21.8 million recognized for the nine months ended September 30, 2026, is typical for attracting and retaining talent in the competitive biotech landscape.
Legal Proceedings
- As of September 30, 2026, the company was not a party to any material legal proceedings or claims.
Stakeholder Impact
- Shareholders may experience dilution due to the issuance of new shares in recent and potential future capital raises.
- The company's ability to achieve profitability and generate significant revenue is dependent on the successful development and commercialization of its product candidates, impacting shareholder value.
- Employees are subject to stock-based compensation plans, which are a significant expense but also a tool for attracting and retaining talent.
Next Steps
- Initiate Phase 3 trials in bipolar disorder in the second half of 2027.
- Initiate Phase 3 trials in PGTCS in the first half of 2027.
- Present additional data from the Phase 2 trial of RAP-219 in bipolar disorder at a future medical meeting.
- Initiate a Phase 1 study for the long-acting injectable (LAI) formulation of RAP-219, with initial PK data expected in Q3 2027.
- Initiate a Phase 1 study for RAP-641 (64 nAChR agonist), with preliminary results expected in the second half of 2027.
- Continue to leverage the RAP technology platform to discover additional product candidates.
Key Dates
| Date | Description |
|---|---|
| 2024-12-31 | End of fiscal year 2025 |
| 2025-03-10 | Form 10-K filing for year ended December 31, 2025 |
| 2025-06-10 | Initial Public Offering (IPO) closing date |
| 2025-07-01 | Common stock sales agreement (ATM Program) established |
| 2025-09-30 | End of nine months period for financial reporting |
| 2025-10-01 | Start of Q4 2025 |
| 2025-12-31 | End of fiscal year 2025 |
| 2026-01-01 | Annual increase in shares available under 2024 Plan |
Recommendation
holdRapport Therapeutics has made significant clinical and financial progress, evidenced by positive trial data and a substantial capital raise. However, the company remains in the early stages of drug development with substantial ongoing losses and inherent risks. While the long-term potential is promising, the path to profitability is long and uncertain, warranting a 'hold' position until further clinical and regulatory milestones are achieved and de-risked.
Keywords
Biotechnology, Neurology, Psychiatry, Clinical Trials, Drug Development, RAP Technology, RAP-219, Seizures
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.